Item 4 is hereby amended and supplemented as follows: On February 8, 2025, in connection with the appointment of Albert A. Holman III to the board of directors of the Issuer, the Sponsor transferred 30,000 Class B ordinary shares held by it to Mr. Holman. As reported by the Issuer on a Current Report on Form 8-K filed on March 3, 2025, on February 28, 2025 (the "Helix 8-K") the Issuer entered into a business combination agreement (the "Business Combination Agreement") by and among the Issuer, Helix II Merger Sub, Inc. ("Merger Sub") and TheRas, Inc. (doing business as BridgeBio Oncology Therapeutics, Inc. "BBOT"). Upon the terms and subject to the conditions of the Business Combination Agreement, (i) Helix will de-register in the Cayman Islands and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation (the "Domestication"), and (ii) following the Domestication, Merger Sub will be merged with and into BBOT, as a result of which BBOT will be the surviving company and a wholly-owned subsidiary of Helix (the "Merger"). The Domestication, Merger, and other transactions contemplated by the Business Combination Agreement are collectively referred to as the "Business Combination," and the consummation of the Merger is referred to as the "Closing" and the date of the Closing is referred to as the "Closing Date." The Domestication will occur on the day that is one business day prior to the Closing Date. Upon the Domestication, it is anticipated that Helix will change its name to "BridgeBio Oncology Therapeutics, Inc." and is referred to herein as "PubCo" as of the time following the Domestication. Immediately prior to the Domestication, (1) Helix will effect the redemption of Helix public shares validly submitted for redemption and not withdrawn, (2) Sponsor will forfeit the Sponsor Forfeited Shares (as defined below), and (3) each holder of each issued and outstanding Class B ordinary share (other than the Sponsor Forfeited Shares) will irrevocably and unconditionally elect to convert, on a one-for-one basis, each Class B ordinary share held by it into one Class A ordinary share (the "Class B Share Conversion"). At the effective time of the Domestication, each outstanding Class A ordinary share (not including public shares validly submitted for redemption nor the Sponsor Forfeited Shares, but including Class A ordinary shares issued upon the Class B Share Conversion) will convert into one share of domesticated common stock, par value $0.0001 per share, of PubCo (the "PubCo Common Stock"). On the day of the Closing, the Merger will occur. At the effective time of the Merger, each share of BBOT's capital stock that is issued and outstanding immediately prior to the Merger (not including treasury shares and dissenting shares) will be automatically canceled and converted into the right to receive the corresponding number of shares of PubCo Common Stock equal to the Consideration Ratio (as defined below). Additionally, at the effective time of the Merger, each outstanding BBOT stock option will become an option of PubCo containing the same terms, conditions, vesting and other provisions as are currently applicable to such BBOT stock options, provided that each option will be exercisable for the number of shares of PubCo Common Stock equal to the Consideration Ratio multiplied by the number of shares of BBOT common stock subject to the option as of immediately prior to the effective time of the Merger, rounded down to the nearest whole share, at an exercise price equal to the per share exercise price of the BBOT option divided by the Consideration Ratio, rounded up to the nearest whole cent. The "Aggregate Merger Consideration" to be issued to BBOT stockholders in connection with the Merger will be determined by dividing (a) $461,051,546 (the "Equity Value") by (b) the price (the "Redemption Price") at which each Class A ordinary share may be redeemed in connection with the Business Combination. The "Consideration Ratio" is the number of shares of PubCo Common Stock to be issued in exchange for issued and outstanding BBOT capital stock upon the Merger, and is equal to the quotient obtained by dividing (x) the Aggregate Merger Consideration by the Aggregate Fully Diluted Company Shares, as defined in the Business Combination Agreement. Pursuant to the Business Combination Agreement, PubCo's board will consist of seven members, with the Sponsor having the right to initially designate two members. The consummation of the Business Combination is subject to, among other things, the approval of the stockholders of both BBOT and Helix, and the satisfaction or waiver of the conditions stated in the Business Combination Agreement. The foregoing description of the Business Combination Agreement is subject to and qualified in its entirety by reference to the full text of the Business Combination Agreement, a copy of which is attached as Exhibit 2.1 to the Helix 8-K, the terms of which are incorporated herein by reference. In connection with the execution of the Business Combination Agreement, on February 28, 2025, certain shareholders and insiders of Helix (the "Helix Supporting Shareholders"), including the Sponsor, Fund III, Fund V, and Master Fund each holding Class A ordinary shares, and the independent directors and an advisor of Helix each holding Class B ordinary shares (the "Helix Existing Investors"), entered into a support agreement with Helix and BBOT (the "Helix Support Agreement"). Under the Helix Support Agreement, among other things, each Helix Supporting Shareholder agreed to vote, at any meeting of the shareholders of Helix, and in any action by written consent of the shareholders of Helix, all of such Helix Supporting Shareholder's Class A ordinary shares and Class B ordinary shares (i) in favor of each of the Parent Proposals (as defined in the Business Combination Agreement), and any other matters necessary or reasonably requested by Helix for consummation of the Domestication, the Merger or any other transactions contemplated by the Business Combination Agreement and the approval of the Parent Proposals; (ii) against any Alternative Proposal or Alternative Transaction or any proposal relating to an Alternative Proposal or Alternative Transaction (as defined in the Business Combination Agreement, respectively); and (iii) in favor of any proposal sought by Helix to extend the deadline by which Helix must consummate its initial business combination. In addition, the Helix Support Agreement prohibits each Helix Supporting Shareholder from, among other things, selling, assigning or transferring any Class A ordinary shares or Class B ordinary shares held by such Helix Supporting Shareholder except to certain permitted transferees, until the earliest of (a) the effective time of the Merger, (b) such date and time as the Business Combination Agreement is terminated in accordance with its terms; (c) the liquidation of Helix; (d) the written agreement of each of the terminating Helix Supporting Shareholder(s), Helix and BBOT with respect to terminating the rights and obligations under the Helix Support Agreement of a specific Helix Supporting Shareholder or a subset of Helix Supporting Shareholders; and (e) the written agreement of all Helix Supporting Shareholders, Helix and BBOT to terminate the Helix Support Agreement in its entirety. Pursuant to the Helix Support Agreement, each of Fund III, Fund V, and Master Fund and its permitted transferees irrevocably and unconditionally covenants and agrees not to submit any Class A ordinary shares owned by it for redemption in connection with the Business Combination. Additionally, the Sponsor and Helix Existing Investors will comply with their non-redemption obligations as specified in the letter agreement they entered into with Helix in connection with Helix's initial public offering. Each of the Sponsor and each Helix Existing Investor agreed to elect to convert their Class B ordinary shares into Class A ordinary shares immediately prior to the Domestication and to waive their rights under Helix's amended and restated memorandum and articles of association to have their Class B ordinary shares converted into Class A ordinary shares at a ratio of greater than one-to-one. In addition, pursuant to the Helix Support Agreement, the Sponsor will, effective as of immediately prior to the Domestication and conditioned upon the Closing, forfeit and surrender to Helix such number of Class B ordinary shares (the "Sponsor Forfeited Shares") held by the Sponsor equal to the quotient of (i) the difference between (A) the Redemption Price multiplied by 4,600,000 less (B) $46,000,000 divided by (ii) the Redemption Price. Further, if and only if Helix Closing Cash (as defined in the Business Combination Agreement) is less than $400,000,000, the Sponsor will forfeit a number of shares of PubCo Common Stock equal to (a) 3,360,000 multiplied by (b) one minus the number resulting from dividing (i) the Helix Closing Cash by (ii) $400,000,000, with any fractional share rounded to the nearest whole number resulting from such product. The foregoing description of the Helix Support Agreement is subject to and qualified in its entirety by reference to the full text of the Helix Support Agreement, a copy of which is attached as Exhibit 10.1 to the Helix 8-K, the terms of which are incorporated herein by reference. In connection with the Business Combination, on February 28, 2025, Helix entered into subscription agreements (the "Subscription Agreements") with certain qualified institutional buyers, institutional accredited investors, and other accredited investors (collectively, the "PIPE Investors"), including Cormorant Asset Management, LP ("Cormorant") on behalf of certain of its investment vehicles, pursuant to which, among other things, PubCo agreed to issue and sell to the PIPE investors, and the PIPE Investors agreed to subscribe for and purchase an aggregate of approximately $260,000,000 of PubCo Common Stock at a purchase price equal to the Redemption Price (the "PIPE Investments"). Cormorant subscribed for an aggregate of $75,000,000 of PIPE Investments. The foregoing description of the Subscription Agreement is subject to and qualified in its entirety by the full text of the Subscription Agreement, a copy of which is included as Exhibit 10.3 to the Helix 8-K, the terms of which are incorporated herein by reference.